MUC1 PARALLEL CAR (pCAR) THERAPEUTIC AGENTS
AssigneesLeucid Bio Ltd, King's College London
InventorsJohn MAHER, Lynsey WHILDING, Fahima KAUSAR, Leena HALIM, Tamara MULIADITAN, Maya GLOVER
Life of this patent
Estimating the term…
Abstract
Provided herein are immunoresponsive cells expressing a MUC1 targeting pCAR comprising a second generation chimeric antigen receptor (CAR) and a chimeric co-stimulatory receptor (CCR). Also provided herein are methods of preparing the immunoresponsive cells and methods of directing T cell mediated immune response using the immunoresponsive cells.
Claims44
An immunoresponsive cell expressing:
- i. a second generation chimeric antigen receptor (CAR) comprising
- a) a signaling region;
- b) a co-stimulatory signaling region;
- c) a transmembrane domain;
- and
- d) a first binding element that specifically interacts with a first epitope on a MUC1 target antigen;
- and
- ii. a chimeric co-stimulatory receptor (CCR) comprising
- e) a co-stimulatory signaling region which is different from that of (b);
- f) a transmembrane domain;
- and
- g) a second binding element that specifically interacts with a second epitope on a second target antigen.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A polynucleotide or set of polynucleotides comprising:
- i. a first nucleic acid encoding a second generation chimeric antigen receptor (CAR) comprising
- a) a signaling region;
- b) a co-stimulatory signaling region;
- c) a transmembrane domain;
- and
- d) a first binding element that specifically interacts with a first epitope on a MUC1 target antigen;
- and
- ii. a second nucleic acid encoding a chimeric co-stimulatory receptor (CCR) comprising
- e) a co-stimulatory signaling region which is different from that of (b);
- f) a transmembrane domain;
- and
- g) a second binding element that specifically interacts with a second epitope on a second target antigen.
37-69. (canceled)
(canceled)
(canceled)
76-79. (canceled)
Dependencies are inferred from the claim text.